X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA UNICHEM LAB NATCO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 19.4 -276.0 - View Chart
P/BV x 18.5 2.0 911.2% View Chart
Dividend Yield % 0.6 1.3 49.1%  

Financials

 NATCO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
UNICHEM LAB
Mar-17
NATCO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs877320 274.1%   
Low Rs424221 191.6%   
Sales per share (Unadj.) Rs223.4167.2 133.6%  
Earnings per share (Unadj.) Rs31.112.0 259.8%  
Cash flow per share (Unadj.) Rs40.316.9 237.9%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.81.1 69.3%  
Book value per share (Unadj.) Rs219.5117.0 187.5%  
Shares outstanding (eoy) m33.0790.88 36.4%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.6 179.9%   
Avg P/E ratio x20.922.6 92.5%  
P/CF ratio (eoy) x16.116.0 101.1%  
Price / Book Value ratio x3.02.3 128.2%  
Dividend payout %16.125.1 64.2%   
Avg Mkt Cap Rs m21,50424,578 87.5%   
No. of employees `000NA5.2 0.0%   
Total wages/salary Rs m1,1282,487 45.3%   
Avg. sales/employee Rs ThNM2,928.3-  
Avg. wages/employee Rs ThNM479.4-  
Avg. net profit/employee Rs ThNM209.4-  
INCOME DATA
Net Sales Rs m7,38915,195 48.6%  
Other income Rs m167110 151.6%   
Total revenues Rs m7,55615,305 49.4%   
Gross profit Rs m1,7931,788 100.3%  
Depreciation Rs m304452 67.4%   
Interest Rs m36634 1,086.6%   
Profit before tax Rs m1,2901,413 91.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309326 94.8%   
Profit after tax Rs m1,0271,087 94.5%  
Gross profit margin %24.311.8 206.3%  
Effective tax rate %23.923.1 103.8%   
Net profit margin %13.97.2 194.4%  
BALANCE SHEET DATA
Current assets Rs m3,6816,426 57.3%   
Current liabilities Rs m3,1233,917 79.7%   
Net working cap to sales %7.616.5 45.8%  
Current ratio x1.21.6 71.9%  
Inventory Days Days8968 132.2%  
Debtors Days Days5977 76.2%  
Net fixed assets Rs m7,6857,410 103.7%   
Share capital Rs m331182 181.9%   
"Free" reserves Rs m6,67010,454 63.8%   
Net worth Rs m7,25910,636 68.2%   
Long term debt Rs m9554 21,702.3%   
Total assets Rs m11,95715,258 78.4%  
Interest coverage x4.542.9 10.5%   
Debt to equity ratio x0.10 31,800.0%  
Sales to assets ratio x0.61.0 62.0%   
Return on assets %11.77.3 158.7%  
Return on equity %14.210.2 138.5%  
Return on capital %20.713.6 152.5%  
Exports to sales %39.424.1 163.1%   
Imports to sales %5.74.9 115.2%   
Exports (fob) Rs m2,9083,666 79.3%   
Imports (cif) Rs m421752 56.0%   
Fx inflow Rs m3,4455,298 65.0%   
Fx outflow Rs m7030-   
Net fx Rs m2,7435,298 51.8%   
CASH FLOW
From Operations Rs m1,440683 210.8%  
From Investments Rs m-1,089-1,316 82.8%  
From Financial Activity Rs m-353592 -59.6%  
Net Cashflow Rs m-1-40 3.7%  

Share Holding

Indian Promoters % 52.0 50.1 103.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 15.1 51.9%  
FIIs % 16.6 3.0 554.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 31.7 82.0%  
Shareholders   25,395 20,176 125.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 25, 2018 03:25 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - DR. REDDYS LAB COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS